Xarelto and Nosebleed - a phase IV clinical study of FDA data
Nosebleed is found among people who take Xarelto, especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months.
The phase IV clinical study analyzes which people take Xarelto and have Nosebleed. It is created by eHealthMe based on reports of 195,181 people who have side effects when taking Xarelto from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
195,181 people reported to have side effects when taking Xarelto.
Among them, 7,535 people (3.86%) have Nosebleed.
What is Xarelto?
Xarelto has active ingredients of rivaroxaban. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 197,108 Xarelto users for its effectiveness, alternative drugs and more.
What is Nosebleed?
Nosebleed (bleeding from nose) is found to be associated with 3,338 drugs and 2,894 conditions by eHealthMe.
Number of Xarelto and Nosebleed reports submitted per year:
Time on Xarelto when people have Nosebleed *:
Gender of people who have Nosebleed when taking Xarelto*:
Age of people who have Nosebleed when taking Xarelto *:
Common drugs people take besides Xarelto *:
Common side effects people have besides Nosebleed *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Xarelto and have Nosebleed?Check whether Nosebleed is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Nosebleed and when was it recovered:
Expand to all the drugs that have ingredients of rivaroxaban:
- Nosebleed and drugs with ingredients of rivaroxaban (6,798 reports)
Alternative drugs to, pros and cons of Xarelto:
- Xarelto (197,108 reports)
Common Xarelto side effects:
- Nosebleed (bleeding from nose): 7,535 reports
- Death: 6,147 reports
- Breathing difficulty: 5,968 reports
- Fatigue (feeling of tiredness): 5,818 reports
Browse all side effects of Xarelto:a b c d e f g h i j k l m n o p q r s t u v w x y z
Nosebleed treatments and more:
- Nosebleed (81,930 reports)
COVID vaccines that are related to Nosebleed:
- Nosebleed in Moderna COVID Vaccine
- Nosebleed in Pfizer BioNTech Covid Vaccine
- Nosebleed in Johnson and Johnson Covid Vaccine
Common drugs associated with Nosebleed:
- Xarelto: 7,535 reports
- Aspirin: 6,510 reports
- Coumadin: 3,010 reports
- Prednisone: 2,977 reports
- Furosemide: 2,875 reports
- Eliquis: 2,609 reports
- Omeprazole: 2,589 reports
- Lasix: 2,551 reports
- Lisinopril: 2,400 reports
- Methotrexate: 2,303 reports
All the drugs that are associated with Nosebleed:
- Nosebleed (3,338 drugs)
Common conditions associated with Nosebleed:
- Atrial fibrillation/flutter: 6,500 reports
- Stroke: 4,890 reports
- High blood pressure: 3,909 reports
- Primary pulmonary hypertension: 3,089 reports
- Rheumatoid arthritis: 2,745 reports
- Pain: 1,900 reports
- High blood cholesterol: 1,796 reports
All the conditions that are associated with Nosebleed:
- Nosebleed (2,894 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on rivaroxaban (the active ingredients of Xarelto) and Xarelto (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Ambisome and Rash Scarlatiniform - 11 seconds ago
- Megace and Infective Pulmonary Exacerbation Of Cystic Fibrosis - 27 seconds ago
- Cromolyn Sodium and Vivelle-Dot drug interaction - 42 seconds ago
- Celebrex and Coronary Artery Thrombosis - 45 seconds ago
- Theophyl and Thrombocythaemia - 46 seconds ago
- Atarax and Tongue Paralysis - 51 seconds ago
- Escitalopram and Encephalitis Herpes - a minute ago
- Farydak and Pulmonary Embolism - a minute ago
- Tofacitinib Citrate and Vistaril drug interaction - a minute ago
- Suboxone and Sprycel drug interaction - a minute ago